首页> 外文期刊>Journal of Drug Delivery >Nanoprodrugs of NSAIDs: Preparation and Characterization of Flufenamic Acid Nanoprodrugs
【24h】

Nanoprodrugs of NSAIDs: Preparation and Characterization of Flufenamic Acid Nanoprodrugs

机译:NSAIDs的纳米前药:氟苯那酸纳米前药的制备和表征

获取原文
       

摘要

We demonstrated that hydrophobic derivatives of the nonsteroidal anti-inflammatory drug (NSAID)flufenamic acid (FA), can be formed into stable nanometer-sized prodrugs (nanoprodrugs) that inhibit the growth of glioma cells, suggesting their potential application as anticancer agent. We synthesized highly hydrophobic monomeric and dimeric prodrugs of FA via esterification and prepared nanoprodrugs using spontaneous emulsification mechanism. The nanoprodrugs were in the size range of 120 to 140 nm and physicochemically stable upon long-term storage as aqueous suspension, which is attributed to the strong hydrophobic interaction between prodrug molecules. Importantly, despite the highly hydrophobic nature and water insolubility, nanoprodrugs could be readily activated into the parent drug by porcine liver esterase, presenting a potential new strategy for novel NSAID prodrug design. The nanoprodrug inhibited the growth of U87-MG glioma cells with IC50of 20 μM, whereas FA showed IC50of 100 μM, suggesting that more efficient drug delivery was achieved with nanoprodrugs.
机译:我们证明了非甾体抗炎药(NSAID)氟苯甲酸(FA)的疏水性衍生物可以形成稳定的纳米级前药(nanoprodrugs),抑制神经胶质瘤细胞的生长,表明它们作为抗癌剂的潜在应用。我们通过酯化反应合成了FA的高疏水性单体和二聚体前药,并利用自发乳化机理制备了纳米前药。纳米前药的大小范围为120至140nm,并且在长期储存为水悬浮液后具有物理化学稳定性,这归因于前药分子之间的强疏水相互作用。重要的是,尽管具有高度疏水性和水不溶性,但纳米前药仍可通过猪肝酯酶容易地活化为母体药物,为新型NSAID前药设计提供了潜在的新策略。纳米前体药物抑制U87-MG神经胶质瘤细胞的生长,IC50为20μm,而FA显示IC50为100μm,这表明纳米前体药物可以更有效地递送药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号